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esponsibility of InstAbstract Stroke is a brain damage caused by a loss of blood supply to a portion of the brain, which requires
prompt and effective treatment. The current pharmacotherapy for ischemic stroke primarily relies on
thrombolysis using recombinant tissue plasminogen activators (rt-PAs) to breakdown blood clots. Neuropro-
tective agents that inhibit excitatory neurotransmitters are also used to treat ischemic stroke but have failed to
translate into clinical beneﬁts. This poses a major challenge in biomedical research to understand what causes
the progressive brain cell death after stroke and how to develop an effective pharmacotherapy for stroke. This
brief review analyzes the fate of about 430 potentially useful stroke medications over the period 1995–2015
and describes in detail those that successfully reached the market. Hopefully, the information from this analysis
will shed light on how future stroke research can improve stroke drug discovery.
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The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015 5231. Introduction
Stroke is the leading cause of death and long-term disability in
China with a population of stroke patients over 7 million1,2. With
the rise in prevalence and trend towards younger patients, stroke
prevalence in China varies from 260 to 719 per 100,000 people for
all ages3. According to the Report on Chinese Stroke Prevention
released in 2015, approximately 15% of people over 40 are
at high risk of stroke with a comprehensive standardized pre-
valence of stroke between 2011 and 2013 of about 2% and an
8.1% rise in prevalence1,4. The prevalence of stroke patients in
urban areas is higher than in rural areas and people in the North of
China have a higher prevalence than those in the South1,5. On the
basis of World Bank Data, China will have 31.77 million stroke
patients by 2030 costing the country as much as $40.0 billion
per year.
Stroke is classiﬁed into either ischemic stroke affecting
approximately 87% of patients or hemorrhagic stroke affecting
the other approximately 13%6. Ischemic stroke is caused by a
reduction in cerebral blood supply, whereas hemorrhagic stroke
results from the rupture of a blood vessel in the brain causing
bleeding into the brain or subarachnoid space. For hemorrhagic
stroke, neurosurgery is required to treat the bleeding. For ischemic
stroke, current interventional treatment regimens mainly include
blood pressure management, catheter-based interventions, throm-
bolytic therapy, anticoagulation therapy, deﬁbrinogen therapy and
pharmacotherapy to improve cerebral blood circulation. This
review is limited to drug therapy of ischemic stroke, which aims
to restore blood ﬂow.
In an effort to gain insight into what makes a stroke drug
succeed in reaching the market, we have examined the fate of
about 430 potential stroke drugs evaluated over the past twenty
years (1995–2015). The analysis was based on data reported fromFigure 1 The landscape of ischemic stroke drug discovery and therapy ov
by pie chart based on the mechanism of action: (B) the 4% of drugs on the
preclinical evaluation and (E) the 70% of failed drug candidates.the Addis Insight Database deposited by December 25, 2015. We
found that approximately 300 drug candidates (70%) were
discontinued, about 70 (17%) are undergoing preclinical assess-
ment, 40 (9%) are in various phases of clinical trials and only 19
(4%) have reached the market (Fig. 1).
The 430 drug candidates can be divided into two main
categories based on their mechanism of action: thrombolytics
and neuroprotective agents. Thrombolytic therapy aims at remov-
ing the thrombus blockage and includes drugs that act as
plasminogen activators, antithrombotic agents and platelet aggre-
gation inhibitors. Neuroprotective agents aim to halt the ischemic
cascade and prevent secondary injuries or at least decrease the loss
of vulnerable neurons in the ischemic penumbra7,8. Neuroprotec-
tive agents act by various mechanisms including as antioxidants,
neuron stimulants, calcium channel antagonists and free radical
scavengers.2. Drugs discontinued in clinical trials
Analyzing the 300 drug candidates that did not reach the market
reveals several interesting aspects. First, 72 (24%) drugs were
thrombolytics and included inhibitors of thrombin, factor Xa,
platelet aggregation and serine endopeptidase (Fig. 1). Of the
remaining 228 failed drugs, 74 (32%) were central nervous system
neuroprotective agents with putative ability to either limit the
toxicity of the major excitatory neurotransmitter glutamate9 or act
as calcium channel antagonists. An example of the latter is the
atypical analgesic ziconotide (trade name Prialt), derived from the
toxin of the cone snail as the synthetic form of an ω-conotoxin
peptide. It was originally launched by Elan Corporation for the
treatment of severe chronic pain where it acts as a selective N-type
voltage-gated calcium channel blocker10. Phase III clinical trialser the period 1995–2015. (A) The classiﬁcation of 430 drug candidates
market; (C) the 9% undergoing clinical trials; (D) the 17% undergoing
Xiaoling Chen, Kewei Wang524for the prevention of ischemic brain damage following stroke and
severe head trauma have been carried out in the United States,
Europe and Japan11.
The classical neuronal excitotoxicity theory is based on the
observation that cerebral ischemic injury causes the release of
L-glutamate. This then activates ionotropic glutamate receptors
(iGluRs) and leads to an overload of Ca2þ inﬂux that ultimately
aggravates ischemic injury and neuronal apoptosis12. It has been
hypothesized that the excitotoxicity is mediated by three main
glutamate receptor subtypes viz. the N-methyl-D-aspartate (NMDA),
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
and kainate receptors. Activation of these receptors is known to
result in neuronal cell death by excessive calcium inﬂux, and that
antagonistic action at iGluRs may promote the survival of neurons13.
The competitive NMDA antagonist selfotel14–16 and the noncompe-
titive NMDA antagonist aptiganel17,18 were effective in preclinical
studies but ineffective in clinical use16,19. Of the AMPA antagonists
ZK 20077520,21 and YM872, the ﬁrst was discontinued in a phase II
clinical trial for stroke in Europe in 1999 and the second even never
reached clinical trial evaluation because of its severe side effects22.
Over the past twenty years, all putative NMDA receptor
antagonists aimed at stroke treatment have failed in clinical
trials23. This strongly suggests that the neuronal excitotoxicity is
mediated by a non-NMDA mechanism, which could involve
proton-sensitive ion channels/exchangers. These include the acid-
sensing ion channel 1a (ASIC1a)24, proton-sensitive cation chan-
nels, ion exchangers25 and transient receptor potential (TRP)
channels. The latter include transient receptor potential canonical
(TRPC) 3/4/6 channels, transient receptor potential melastatin
(TRPM) 2/4/7 channels and transient receptor potential vanilloid
(TRPV) 1/3/4 channels26–30. Thus drugs that act through non-
glutamate–related mechanisms may represent an alternative strat-
egy for stroke drug discovery.
3. Drugs currently undergoing clinical trials
There are about 40 drug candidates currently in clinical develop-
ment, of which 14 (35%) are in phase I, 15 (38%) in phase II and
11 (27%) in phase III clinical trials. In terms of their mechanism of
action, the drugs include 13 (32%) thrombus-related candidates
and 27 neuroprotective agents (68%). The thrombus-related drug
candidates include inhibitors of carboxypeptidase U, factor Xa and
thrombin, whereas the neuroprotective agents act mainly as cell
replacements, antioxidants and potassium channel antagonists.
Edaravone, ﬁrst developed by the Mitsubishi Corporation, is a
free radical scavenger which protects against cerebrovascular
damage. Borneol, described in the Bencao Gangmu (Compendium
of Materia Medica), is a terpene bicyclic organic compound used
in traditional Chinese medicine (TCM) as moxa. Simcere, a
Shanghai-based company, introduced the new idea of using
edaravone combined with borneol to treat acute ischemic stroke.
The novelty is that borneol enhances the ability of edaravone to
scavenge free radicals through accelerating its distribution. From
2013 to 2015, Simcere enrolled 400 acute ischemic stroke patients
in a phase II clinical trial to determine the efﬁcacy of the
combination (NCT01929096; SIM-23-01)31. Subsequently, Sim-
cere initiated a phase III trial to evaluate the safety and efﬁcacy of
the combination (NCT02430350; SIM-23-02)32 intending to enroll
about 1200 patients. This interesting combination raises the
possibility that combining a natural TCM with a small molecule
medicine is a useful strategy for the development of effective
stroke pharmacotherapy.4. Drugs currently in clinical use
As shown in Table 1, there are 19 stroke drugs currently marketed
in various countries. Among them, 11 are thrombus-dissolving
agents divided into three categories, namely rt-PAs, antithrombotic
agents and platelet aggregation inhibitors. The remaining 8 drugs
are neuroprotective agents that include antioxidants, TCMs,
calcium channel antagonists and neurostimulants. As regards their
route of administration, 14 are used orally and 5 by intravenous
injection, suggesting that most drugs are used to prevent stroke
and its reoccurrence.
Considering where the drugs were launched, the United States
ranks number 1 for the number of drugs launched followed by
Europe and then Asia with China ranked in the 10th place. The top
three organizations for the development of stroke drugs are Boehrin-
ger Ingelheim, Mitsubishi Tanabe Pharma Corporation and Pﬁzer.
The 11 drugs for thrombolysis can be divided into three
categories: rt-PAs, antithrombotic agents, and platelet aggregation
inhibitors.4.1. Recombinant tissue plasminogen activators (rt-PAs)
The rt-PAs for the treatment of acute ischemic stroke include
alteplase, reteplase, and tenecteplase33. Alteplase developed by
Boehringer Ingelheim and approved in 1996 is a recombinant
tissue-type plasminogen activator/serine protease that catalyzes the
conversion of plasminogen to plasmin resulting in clot breakdown.
It is used clinically to treat embolic or thrombotic stroke but not
hemorrhagic stroke or head trauma. Reteplase is more convenient to
administer and produces a more rapid thrombolytic effect than
alteplase. Tenecteplase gives rise to fewer bleeding complications
but has a similar mortality rate after one-year treatment to that of
alteplase. Other rt-PAs such as desmoteplase are still in clinical
development.
In July 2015, the Medicines and Healthcare Products Regula-
tory Agency (MHRA) reconﬁrmed that the beneﬁts of alteplase
outweigh the risks of acute ischemic stroke34. This positive
conclusion was based on evidence and reviews of clinical
trials35–37. Nevertheless, due to its narrow therapeutic window of
4.5 h and the high risk of intracranial hemorrhage, only about 5%
of stroke patients beneﬁt from alteplase treatment25.4.2. Antithrombotic agents
There are currently ﬁve antithrombotic agents in clinical use
including argatroban, rivaroxaban, apixaban, dabigatran etexilate,
and edoxaban38,39. Argatroban is a potent, reversible thrombin
inhibitor used in Japan since 1996. Rivaroxaban is the ﬁrst orally
available direct factor Xa inhibitor launched in 2013. Apixaban,
another oral pyrazole-based factor Xa inhibitor, was launched in
14 countries in late 2014 (December 31). It provides greater
thrombin inhibition and a better tolerability proﬁle than conven-
tional antithrombotic drugs such as warfarin40–42. Dabigatran
etexilate, the oral double prodrug of dabigatran, is a new
generation of oral anticoagulant that has been marketed by
Boehringer Ingelheim in 14 countries since 2015 for stroke
prophylaxis. Edoxaban, a small molecule compared with antic-
oagulants like heparin and warfarin, is expected to have better oral
absorption and a lower risk of bleeding. Daiichi Sankyo launched
the product in 2015 in China, Japan, the United States and United
Kingdom.
Table 1 Current stroke drugs in the market.
Name Chemical class Mechanism Administration Market
time
Location Organization
A, rt-PAs thrombolysis
1 Alteplase Recombinant proteins Plasminogen activators Treatment IV 1997/12/1 World Boehringer
Ingelheim
B, Antithrombotic agents
2 Argatroban Pipecolic acids; small
molecules
Thrombin inhibitors Treatment 1996/8/2 Japan Mitsubishi
Chemical Daiichi
Sankyo
Company
IV; infusion
3 Rivaroxaban Amides; morpholines;
oxazolidinones; small
molecules; thiophenes
Factor Xa inhibitors Prevention 2013/1/1 Africa, Asia, Canada, European Union,
Japan, Latin America, Middle East, USA,
United Kingdom
Bayer; Johnson &
Johnson
Pharmaceutical;
McMaster
University
PO
4 Apixaban Two-ring heterocyclic
compounds; amides;
lactams; phenyl ethers
pyrazoles; pyridones; small
molecules
Factor Xa inhibitors Prevention 2014/12/
31
Argentina, Australia, Brazil, Canada,
European Union, Hong Kong, Iceland,
Israel, Japan, Mexico, Norway, Turkey,
USA
Bristol-Myers
Squibb; PﬁzerPO
5 Dabigatran etexilate Benzimidazoles; pyridines;
small molecules
Thrombin inhibitors Prevention 2015/3/17 Australia, Canada, China, European
Union, Hong Kong, Japan, Malaysia, New
Zealand, Philippines, Singapore, South
Africa, South Korea, Taiwan, Thailand,
Turkey, USA
Boehringer
IngelheimPO
6 Edoxaban Small molecules Factor Xa inhibitors Prevention 2015/7/9 China, Japan, USA, United Kingdom Daiichi Sankyo
CompanyPO
C, Antiplatelet drugs
7 Cilostazol Small molecules; tetrazoles Platelet aggregation inhibitors; type 3 cyclic
nucleotide phosphodiesterase inhibitors
Prevention 2012/1/25 China, Japan Otsuka
Pharmaceutical;
Pﬁzer
PO
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Table 1 (continued )
Name Chemical class Mechanism Administration Market
time
Location Organization
8 Clopidogrel Two-ring heterocyclic
compounds;
chlorobenzenes; esters;
pyridines; small molecules;
thienopyridines
Platelet ADP receptor antagonists; platelet
aggregation inhibitors; purinergic P2 receptor
antagonists
Treatment 2006/5/5 Brazil, Chile, China, Colombia, Croatia,
European Union, Japan, Mexico, New
Zealand, Norway, Philippines, Puerto
Rico, Russia, South Korea, Switzerland,
Turkey, USA
Bristol-Myers
Squibb; SanoﬁPO;
Intracoronary
9 Clopidogrel (Hanmi
Pharmaceutical)
Treatment 2015/3/13 Cyprus, Germany, Italy, Netherlands,
Portugal, South Korea, Spain, United
Kingdom
Hanmi
PharmaceuticalsPO
10 Aspirin controlled
release (New Haven
Pharmaceuticals)
Salicylic acids; small
molecules
Cyclooxygenase inhibitors; nitric oxide stimulants;
platelet aggregation inhibitors
Prevention 2015/12/
15
USA New Haven
PharmaceuticalsPO
11 Aspirin/
dipyridamole
extended release
Salicylates; small
molecules; vasodilators
Platelet aggregation inhibitors Prevention 2008/5/19 Australia, Canada, Europe, South Africa,
South America, USA
Boehringer
IngelheimPO
12 Hydrochlorothiazide/
atenolol/ramipril/
simvastatin/aspirin
or Polycap
Benzothiadiazines;
heterocyclic bicyclo
compounds; naphthalenes;
propanolamines;
salicylates; small molecules
Antihyperlipidaemics; antihypertensives; platelet
aggregation inhibitors; ACE inhibitors; β1
adrenergic receptor antagonists; cyclooxygenase
inhibitors; HMG-CoA reductase inhibitors; thiazide
diuretics
Prevention 2009/8/1 India Cadila
PharmaceuticalsPO
D, Neuroprotective agents
13 Gingko mihuan Flavonoids; glycosides;
terpenes; traditional
Chinese medicine
Antioxidants; platelet activating factor inhibitors Treatment 2012/7/17 China Tianyin
PharmaceuticalPO
14 Lumbricus rubellus
extract
Alternative medicine;
enzymes; thrombolytics;
traditional Chinese
medicine
Fibrin inhibitors; ﬁbrinolytic agents; Janus kinase
1 inhibitors; matrix metalloproteinase 9 inhibitors;
NF-κB inhibitors; platelet aggregation inhibitors;
STAT1 transcription factor inhibitors; tumor
necrosis factor α inhibitors
Treatment 2012/8/8 Indonesia Dexa Medica
PO
15 Fasudil (QR Science
and Technology)
Amines; isoquinolines;
small molecules;
sulfonamides
Calcium channel antagonists; protein kinase C
inhibitors; Rho-associated kinase inhibitors
Treatment 2013/1/1 China QR Science and
TechnologyParenteral
16 Cerebrolysin Nootropics; peptides Neuron stimulants Treatment IV 2000/3/22 Austria, Germany EVER Neuro
Pharma
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The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015 5274.3. Antiplatelet drugs
Antiplatelet drugs such as cilostazol, clopidogrel and aspirin decrease
platelet aggregation and interfere with thrombus formation. They are
effective in improving arterial circulation which is largely unaffected
by anticoagulants. Cilostazol is a 2-oxoquinoline derivative used in the
alleviation of intermittent claudication in individuals with peripheral
vascular disease. It is a phosphodiesterase inhibitor that induces direct
arterial vasodilation and was launched in China and Japan for stroke
prevention by Otsuka Pharmaceuticals in January of 2012. Clopidogrel
is an orally available thienopyridine derivative co-developed by Sanoﬁ
and Bristol-Myers Squibb which acts to selectively inhibit adenosine
diphosphate (ADP)-induced platelet aggregation by antagonizing
platelet ADP and purinergic P2 receptors. Hanmi Pharmaceuticals
launched a safer, more effective and convenient formulation of
clopidogrel incorporating the napadisilate salt in March of 2015.
Aspirin is an irreversible cyclooxygenase inhibitor undergoing
development as a once-daily controlled release formulation for
secondary stroke prevention. A combination of aspirin and
dipyridamole has been developed to reduce the risk of ischemic
stroke recurrence. Another combination medication for stroke
prevention is the so-called Polycap, a “ﬁve-in-one” capsule
launched in India by Cadila Pharmaceuticals Ltd. in August of
2009. The Polycap contains atenolol, ramipril, hydrochlorothia-
zide, aspirin and simvastatin43,44, each of which has been
previously shown to reduce cardiovascular events. The advantage
of Polycap is its potential to prevent stroke in high risk patients
with hypertension, diabetes, dyslipidemia, and smoking.4.4. Neuroprotective agents
There are several neuroprotective agents available for the treat-
ment of ischemic stroke, including natural products, ion channel
regulators and endogenous metabolites. Their primary aim is to
alleviate excitotoxicity, calcium dysregulation, mitochondrial
dysfunction, oxidative and nitrosative stress and inﬂammation.
In addition, they act to relieve tissue acidosis, blood-brain barrier
disruption, and neuronal apoptosis, necrosis and autophagy45.4.4.1. Natural products
Gingko mihuan is a TCM launched as a proprietary prescription
oral liquid by Tianyin Pharmaceuticals in 2012. The product
contains ﬂavonoid and terpenoid gingko extracts. Flavonoids have
been shown to possess potent antioxidant activity and are useful
in reducing capillary fragility. Terpenoids are reported to inhibit
platelet activating factor and reduce blood viscosity associated
with certain cardiovascular disorders. Gingko Mihuan Oral Liquid
was approved by the China Food and Drug Administration
(CFDA) in 2012 and is commonly prescribed for the treatment
of stroke. Tianyin Pharmaceuticals also plans to develop capsule
and tablet formulations of Gingko mihuan.
In August 2012, Dexa Medica, Indonesia introduced an oral
tablet containing a bioactive protein fraction extracted from
Lumbricus rubellus (red earthworm) as an anticoagulant for the
treatment of ischemic stroke. The extract contains eight under
100 kDa proteins, one of which is a serine protease enzyme with
thrombolytic and ﬁbrinolytic effects similar to those of lumbro-
kinase46. In November 2014, Dexa Medica began phase II/III
trials to assess the effects of the medication in patients with acute
ischemic stroke (NCT0179099747; NCT0213352148).
Xiaoling Chen, Kewei Wang528Butylphthalide (3-n-butylphthalide, NBP), isolated from the
seeds of celery, is another natural product found to protect against
ischemic brain injury by increasing blood ﬂow49,50. In 2005, NBP
was approved by the CFDA to undergo clinical trials for the
treatment of cerebral ischemia. Currently, a phase IV clinical trial
is ongoing51.4.4.2. Ion channel regulators
Ion channels are membrane proteins that mediate ionic home-
ostasis in neurovascular units during ischemic stroke. An excess of
sodium inﬂux to neurons induces nerve cell swelling and leads to
cytotoxic edema. Intracellular calcium overload can trigger a series
of pathological events that ultimately result in neuronal apoptosis
as well as necrotic death. An unchecked outﬂow of potassium
changes neuronal polarization and excitability. Therefore, modula-
tion of ion channel function is a novel approach to the treatment of
stroke.
Fasudil mesylate, developed by QR Science and Technology, is
an injectable formulation approved by the CFDA in 2013 for the
treatment of cerebral infarction. The mechanism of action includes
inhibiting a rho-kinase52, vasodilation53 and inﬂuencing intracel-
lular calcium. Fasudil has been shown to enhance motor recovery
after ischemic stroke caused by middle cerebral artery occlusion in
rats54. It was also shown to reduce ASIC1a expression and calcium
currents in the treatment group. This indicates that fasudil
inﬂuences intracellular calcium levels through regulating the
ASIC1a channel55.4.4.3. Other neuroprotective agents
Nootropics, also called smart drugs or cognitive enhancers, are
supplements or endogenous substances that improve cognitive
function and behavioral outcome in healthy individuals and
patients probably by promoting neurogenesis or decreasing neu-
ronal death. Supplementing endogenous substances, such as
neurotrophic factors, intermediates of phosphatidylcholine and
urinary kallidinogenase, may constitute an effective approach for
alleviating stroke symptoms.
Cerebrolysin is a mixture of low molecular weight peptides and
amino acids derived from pig brain that has been shown to
facilitate neural growth and survival of cholinergic neurons. The
drug mainly consists of brain-derived neurotrophic factor (BDNF),
nerve growth factor (NGF), glial cell line-derived neurotrophic
factor (GDNF), and ciliary neurotrophic factor (CNTF)56. It
improves neurological outcome through neurogenesis induced by
proliferation, differentiation, and migration of adult subventricular
zone neural progenitor cells through the PI3K/Akt pathway57.
Cerebrolysin was approved in March 2000 in Austria and
Germany for the treatment of stroke. However, at the present
time, there is insufﬁcient evidence to evaluate the effects of
cerebrolysin on survival and dependency in people with acute
ischemic stroke. This will require a high-quality, large-scale,
randomized clinical trial58,59.
Citicoline, a derivative of choline and cytidine, is a psychos-
timulant or nootropic. It is an intermediate in the biosynthesis of
phosphatidylcholine, an important component of the neural cell
membrane that is degraded to free fatty acids and free radicals
during cerebral ischemia. Its neuroprotective action may involve
increasing phosphatidylcholine synthesis, stimulating glutathione
synthesis to scavenge hydroxy radicals, and reducing the elevated
levels of arachidonic acid that occur after an ischemic stroke60. An
oral syrup of citicholine was launched in more than 20 countriesaround the world for the treatment of ischemic stroke in 1998.
Subsequently, intravenous and intramuscular formulations of the
drug were approved in Argentina, Austria, Chile, Indonesia,
Mexico, Portugal, Thailand and Venezuela in 2013. However, in
some placebo-controlled studies, citicoline was found to be
ineffective in the treatment of moderate-to-severe acute ischemic
stroke61,62.
Kailikang is an injectable formulation of urinary kallidinogen-
ase developed by Techpool Bio-Pharma, Guangzhou, China. It is a
proteolytic enzyme extracted from human urine that converts
kininogen to kinin and kallidin in the treatment of thrombotic
cerebral infarction. The product has been shown to expand arteries
in vitro, inhibit platelet aggregation, promote deformability and
oxygen separation ability of haemocytes, and inhibit apoptosis and
inﬂammation63. Due to its efﬁcacy, the product was launched in
China in 200564.5. Concluding remarks
Analyzing the fate of 430 drugs evaluated for the treatment of
ischemic stroke over the period 1995–2015 reveals that only 19
drugs (4%) were successful in reaching the market. Among them,
11 drugs are antithrombotic and 8 are used for stroke prevention.
This indicates thrombolytic therapy remains the dominant form of
pharmacotherapy for ischemic stroke.
Based on the mechanism of action of the failed candidates, it
appears that drugs targeting non-NMDA-mediated calcium transport
represent a promising strategy for stroke drug discovery. For
example, fasudil mesylate improves neurological deﬁcit and neuronal
damage in rats by inhibiting ASIC1a. The cocktail of Polycap that
combines ﬁve different medications in a single, once-a-day pill is also
used for preventing strokes, suggesting combined medications may
be worth further exploration. One such combination containing
edaravone and borneol is currently undergoing a phase III clinical
trial, the outcome of which certainly deserves attention.
It is also noteworthy that natural products, such as Gingko
mihuan and Lumbricus rubellus extract, have been approved for
stroke protection and treatment. This suggests that drugs with
multiple targets have potential for neuronal protection and
effective pharmacotherapy of ischemic stroke.
References
1. Wang LD. In: Report on the Chinese stroke prevention. Beijing:
Pecking Union Medical College Press; 2015.
2. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China:
huge burden, signiﬁcant workload, and a national priority. Stroke
2011;42:3651–4.
3. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in
China: epidemiology, prevention, and management strategies. Lancet
Neurol 2007;6:456–64.
4. Wang YL, Zhao XQ, Jiang Y, Li H, Wang LM, Johnston SC, et al.
Prevalence, knowledge, and treatment of transient ischemic attacks in
China. Neurology 2015;84:2354–61.
5. Wu XM, Zhu B, Fu LY, Wang HL, Zhou B, Zou SF, et al. Prevalence,
incidence, and mortality of stroke in the chinese island populations: a
systematic review. PLoS One 2013;8:e78629.
6. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman
M, et al. Heart disease and stroke statistics—2016 update: a report
from the american heart association. Circulation 2016;133:e38–60.
7. Casson RJ, Chidlow G, Ebneter A, Wood JP, Crowston J, Goldberg I.
Translational neuroprotection research in glaucoma: a review of
deﬁnitions and principles. Clin Exp Ophthalmol 2012;40:350–7.
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015 5298. Seidl SE, Potashkin JA. The promise of neuroprotective agents in
Parkinson's disease. Front Neurol 2011;2:68.
9. Guyot LL, Diaz FG, O'Regan MH, McLeod S, Park H, Phillis JW.
Real-time measurement of glutamate release from the ischemic
penumbra of the rat cerebral cortex using a focal middle cerebral
artery occlusion model. Neurosci Lett 2001;299:37–40.
10. Miljanich GP. Ziconotide: neuronal calcium channel blocker for
treating severe chronic pain. Curr Med Chem 2004;11:3029–40.
11. Heading CE. Ziconotide (Elan Pharmaceuticals). IDrugs 2001;4:339–
50.
12. Lipton SA, Rosenberg PA. Excitatory amino acids as a ﬁnal common
pathway for neurologic disorders. New Eng J Med 1994;330:613–22.
13. Muir KW, Lees KR. Clinical experience with excitatory amino acid
antagonist drugs. Stroke 1995;26:503–13.
14. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB,
et al. Safety and tolerability of the glutamate antagonist CGS 19755
(Selfotel) in patients with acute ischemic stroke. Results of a phase IIa
randomized trial. Stroke 1995;26:602–5.
15. Stewart L, Bullock R, Teasdale GM, Wagstaff A. First observations of
the safety and tolerability of a competitive antagonist to the glutamate
NMDA receptor (CGS 19755) in patients with severe head injury. J
Neurotrauma 1999;16:843–50.
16. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G,
et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of
an NMDA antagonist. Stroke 2000;31:347–54.
17. Chan PH. The N-methyl-D-aspartate antagonist CNS 1102 protects
cerebral gray and white matter from ischemic injury following
temporary focal ischemia in rats. Editorial Comment. Stroke
2000;31:1714.
18. Schabitz WR, Li FH, Fisher M. The N-methyl-D-aspartate antagonist
CNS 1102 protects cerebral gray and white matter from ischemic
injury following temporary focal ischemia in rats. Stroke
2000;31:1709–14.
19. Albers GW, Goldstein LB, Hall D, Lesko LM. Aptiganel Acute Stroke
Investigators. Aptiganel hydrochloride in acute ischemic stroke: a
randomized controlled trial. J Am Med Assoc 2001;286:2673–82.
20. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider
HH, et al. ZK200775: a phosphonate quinoxalinedione AMPA
antagonist for neuroprotection in stroke and trauma. Proc Natl Acad
Sci U S A 1998;95:10960–5.
21. Walters MR, Kaste M, Lees KR, Diener HC, Hommel M, De Keyser J,
et al. The AMPA antagonist ZK 200775 in patients with acute
ischaemic stroke: a double-blind, multicentre, placebo-controlled
safety and tolerability study. Cerebrovasc Dis 2005;20:304–9.
22. Terai K, Suzuki M, Sasamata M, Yatsugi SI, Yamaguchi T, Miyata K.
Effect of AMPA receptor antagonist YM872 on cerebral hematoma
size and neurological recovery in the intracerebral hemorrhage rat
model. Eur J Pharmacol 2003;467:95–101.
23. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical
trials for stroke and traumatic brain injury? Lan Neurol 2002;1:383–6.
24. O'Bryant Z, Vann KT, Xiong ZG. Translational strategies for
neuroprotection in ischemic stroke—focusing on acid-sensing ion
channel 1a. Transl Stroke Res 2014;5:59–68.
25. Leng TD, Shi YJ, Xiong ZG, Sun DD. Proton-sensitive cation
channels and ion exchangers in ischemic brain injury: new therapeutic
targets for stroke? Prog Neurobiol 2014;115:189–209.
26. Zhang E, Liao P. Brain transient receptor potential channels and
stroke. J Neurosci Res 2015;93:1165–83.
27. Romero JR, Ridker PM, Zee RY. Gene variation of the transient
receptor potential cation channel, subfamily M, member 7 (TRPM7),
and risk of incident ischemic stroke: prospective, nested, case-control
study. Stroke 2009;40:2965–8.
28. Gelderblom M, Melzer N, Schattling B, Göb E, Hicking G, Aruna-
chalam P, et al. Transient receptor potential melastatin subfamily
member 2 cation channel regulates detrimental immune cell invasion
in ischemic stroke. Stroke 2014;45:3395–402.
29. Xu XS, Wang PJ, Zhao ZG, Cao TB, He HB, Luo ZD, et al.
Activation of transient receptor potential vanilloid 1 by dietarycapsaicin delays the onset of stroke in stroke-prone spontaneously
hypertensive rats. Stroke 2011;42:3245–51.
30. Simard JM, Tarasov KV, Gerzanich V. Non-selective cation channels,
transient receptor potential channels and ischemic stroke. Biochim
Biophys Acta 2007;1772:947–57.
31. ClinicalTrials. gov [Internet]. China: compound edaravone injection
for acute ischemic stroke. A multi-center, randomized, double-blind,
multi-dose, parallel, and controlled phase II trial. [updated 01.07.15].
Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01929096?
term¼NCT01929096&rank¼1〉.
32. ClinicalTrials. gov [Internet]. China: compound edaravone injection
for acute ischemic stroke. A multi-center, randomized, double-blind,
parallel, and active-controlled phase III trial. [updated 19.04.16].
Available from: 〈https://clinicaltrials.gov/ct2/show/NCT02430350?
term¼NCT02430350&rank¼1〉.
33. Verstraete M. Third-generation thrombolytic drugs. Am J Med
2000;109:52–8.
34. Hudson I. Alteplase for ischaemic stroke–responses. Lancet
2014;384:662–3.
35. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E,
et al. Effect of treatment delay, age, and stroke severity on the effects
of intravenous thrombolysis with alteplase for acute ischaemic stroke:
a meta-analysis of individual patient data from randomised trials.
Lancet 2014;384:1929–35.
36. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray
G, et al. The beneﬁts and harms of intravenous thrombolysis with
recombinant tissue plasminogen activator within 6 h of acute ischae-
mic stroke (the third international stroke trial [IST-3]): a randomised
controlled trial. Lancet 2012;379:2352–63.
37. Wardlaw J, Dennis M, Cohen G, Murray G, Innes K, Whiteley M,
et al. Effect of thrombolysis with alteplase within 6 h of acute
ischaemic stroke on long-term outcomes (the third International Stroke
Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
Lancet Neurol 2013;12:768–76.
38. Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin,
dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial
ﬁbrillation. Pharmacoeconomics 2014;32:601–12.
39. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban,
dabigatran, and rivaroxaban versus warfarin for stroke prevention in
non-valvular atrial ﬁbrillation: a cost-effectiveness analysis. Clin Drug
Investig 2014;34:9–17.
40. Halvorsen S, Atar D, Yang HQ, De Caterina R, Erol C, Garcia D, et al.
Efﬁcacy and safety of apixaban compared with warfarin according to
age for stroke prevention in atrial ﬁbrillation: observations from the
ARISTOTLE trial. Eur Heart J 2014;35:1864–72.
41. Goto S, Zhu J, Liu LS, Oh BH, Wojdyla DM, Aylward P, et al.
Efﬁcacy and safety of apixaban compared with warfarin for stroke
prevention in patients with atrial ﬁbrillation from East Asia: a
subanalysis of the apixaban for reduction in stroke and other
thromboembolic events in atrial ﬁbrillation (ARISTOTLE) trial. Am
Heart J 2014;168:303–9.
42. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S,
et al. Efﬁcacy and safety of apixaban compared with warfarin at
different levels of predicted international normalized ratio control for
stroke prevention in atrial ﬁbrillation. Circulation 2013;127:2166–76.
43. Urquhart J. The indian polycap study (TIPS). Lancet 2009;374:781–2.
44. Indian Polycap Study, Yusuf S, Pais P, Afzal R, Xavier D, Teo K,
et al. Effects of a polypill (Polycap) on risk factors in middle-aged
individuals without cardiovascular disease (TIPS): a phase II, double-
blind, randomised trial. Lancet 2009;373:1341–51.
45. Jeyaseelan K, Lim KY, Armugam A. Neuroprotectants in stroke
therapy. Expert Opin Pharmacother 2008;9:887–900.
46. Trisina J, Sunardi F, Suhartono MT, Tjandrawinata RR. DLBS1033, a
protein extract from Lumbricus rubellus, possesses antithrombotic and
thrombolytic activities. J Biomed Biotechnol 2011;2011:519652.
47. ClinicalTrials. gov [Internet]. Indonesia: the role of DLBS1033 in
evaluating bleeding proﬁle and clinical outcome in patients with acute
ischemic stroke: comparison with aspirin and clopidogrel. [updated
Xiaoling Chen, Kewei Wang53003.06.14]. Available from: 〈https://clinicaltrials.gov/ct2/show/
NCT01790997?term¼NCT01790997&rank¼1〉.
48. ClinicalTrials. gov [Internet]. Indonesia: addition of DLBS1033 to
standard therapy for acute ischemic stroke patients; [updated
13.06.16]. Available from: 〈https://clinicaltrials.gov/ct2/show/
NCT02133521?term¼NCT02133521&rank¼1〉.
49. Zhang T, Yan WH, Li Q, Fu JL, Liu KY, Jia WP, et al. 3-n-
Butylphthalide (NBP) attenuated neuronal autophagy and amyloid-β
expression in diabetic mice subjected to brain ischemia. Neurol Res
2011;33:396–404.
50. Ji XC, Zhao WH, Cao DX, Shi QQ, Wang XL. Novel neuroprotectant
chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium
channel TREK-1. Acta Pharmacol Sin 2011;32:182–7.
51. ClinicalTrials. gov [Internet]. China: the impact of NBP on the
collateral circulation in ICAM1 occlusion (INCIMO). [updated
17.04.16]. Available from: 〈https://clinicaltrials.gov/ct2/show/
NCT02594995?term¼NBP&rank¼1〉.
52. Ding J, Li QY, Yu JZ, Wang X, Sun CH, Lu CZ, et al. Fasudil, a Rho
kinase inhibitor, drives mobilization of adult neural stem cells after
hypoxia/reoxygenation injury in mice. Mol Cell Neurosci 2010;43:201–8.
53. Okamura N, Saito M, Mori A, Sakamoto K, Kametaka S, Nakahara T,
et al. Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal
arterioles in stroke-prone spontaneously hypertensive rats. J Ocul
Pharmacol Ther 2007;23:207–12.
54. Liu YH, Zhao Y, Huang FZ, Chen YH, Wang HX, Bonney E, et al.
Combination of early constraint–induced movement therapy and
fasudil enhances motor recovery after ischemic stroke in rats. Int J
Neurosci 2016;126:168–73.
55. Wang J, Wen CY, Cui CC, Xing Y. Effect of activation of the
Ca2þ-permeable acid-sensing ion channel 1a on focal cerebral ische-
mia in diabetic rats. Int J Clin Exp Pathol 2015;8:13255–60.56. Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS.
Cerebrolysin, a mixture of neurotrophic factors induces marked
neuroprotection in spinal cord injury following intoxication of
engineered nanoparticles from metals. CNS Neurol Disord Drug
Targets 2012;11:40–9.
57. Zhang CL, Chopp M, Cui YS, Wang L, Zhang RL, Zhang L, et al.
Cerebrolysin enhances neurogenesis in the ischemic brain and
improves functional outcome after stroke. J Neurosci Res
2010;88:3275–81.
58. Ziganshina LE, Abakumova T. Cerebrolysin for acute ischaemic
stroke. Cochrane Database Syst Rev 2015:6 CD007026.
59. Ziganshina LE, Abakumova T, Kuchaeva A. Cerebrolysin for acute
ischaemic stroke. Cochrane Database Syst Rev 2010:14 CD007026..
60. Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in
transient forebrain ischemia of gerbils. J Neurosci Res 1999;58:697–
705.
61. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J,
Martínez-Vila E, et al. Citicoline in the treatment of acute ischaemic
stroke: an international, randomised, multicentre, placebo-controlled
study (ICTUS trial). Lancet 2012;380:349–57.
62. Alberts MJ. ACP journal club. Citicoline did not improve recovery at
90 days after moderate-to-severe acute ischemic stroke. Ann Intern
Med 2012;157:JC3–13.
63. Xia CF, Yin H, Yao YY, Borlongan CV, Chao L, Chao JL. Kallikrein
protects against ischemic stroke by inhibiting apoptosis and inﬂamma-
tion and promoting angiogenesis and neurogenesis. Hum Gene Ther
2006;17:206–19.
64. Zhang CF, Tao WD, Liu M, Wang DR. Efﬁcacy and safety of human
urinary kallidinogenase injection for acute ischemic stroke: a systema-
tic review. J Evid Based Med 2012;5:31–9.
